12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending
Key Takeaways
The CMS plan-of-care condition requires albumin, body weight and hemoglobin to be measured at least monthly, and hemodialysis adequacy to be assessed at least monthly (PD at least every 4 months).
The CMS survey tool lists calcium and phosphorus monthly, intact PTH every 3 months, and phosphorus of 3.5–5.5 mg/dL; KDIGO 2017 advises lowering elevated phosphate toward the normal range.
Corrected calcium = measured calcium + 0.8 × (4.0 − albumin); KDIGO no longer recommends the calcium-phosphorus product, which was a KDOQI 2003 target (below 55 mg²/dL²).
In dialysis, KDIGO suggests keeping intact PTH at about 2–9 times the assay's upper limit of normal and acting on trends rather than single values.
The CMS survey tool lists albumin of at least 4.0 g/dL by bromocresol green, or the lab's normal range when bromocresol purple (which reads lower) is used.
Why laboratory surveillance matters
In advanced CKD and on dialysis, the kidneys no longer regulate potassium, phosphorus, acid–base balance or nitrogen waste, so routine labs stand in for the missing physiology. For the renal dietitian, the monthly panel is the main monitoring and evaluation tool in the Nutrition Care Process. Three sources set the rules: what the Conditions for Coverage (CfC) require, what the CMS Measures Assessment Tool (MAT) tells surveyors to look for, and what current KDOQI and KDIGO guidelines recommend.
What is required, and how often
| Test | Minimum frequency | Source |
|---|---|---|
| Serum albumin | At least monthly | CfC plan of care, 42 CFR 494.90(a)(2) |
| Body weight | At least monthly (every treatment in practice) | CfC 494.90(a)(2); KDOQI 2020 1.1.5 |
| Hemoglobin or hematocrit | At least monthly | CfC 494.90(a)(4) |
| HD adequacy (delivered Kt/V or equivalent) | At least monthly | CfC 494.80(c)(1) |
| PD adequacy (weekly Kt/V or equivalent) | At least every 4 months (MAT: also in the first month) | CfC 494.80(c)(2) |
| Calcium and phosphorus | Monthly | MAT; KDIGO 2017 suggests every 1–3 months in G5D |
| Intact PTH | Every 3 months | MAT; KDIGO 2017 suggests every 3–6 months in G5D |
| Alkaline phosphatase | At least every 12 months, more often if PTH is high | KDIGO 2017 (G4–G5D) |
| Ferritin and TSAT | Every 1–3 months on HD; every 3 months on PD or without dialysis | KDIGO 2026 anemia |
| 25-hydroxyvitamin D | Baseline, then repeat based on values and treatment | KDIGO 2017 |
| Potassium, bicarbonate, BUN, creatinine, glucose | Monthly panel | Standard practice |
| HbA1c (with diabetes) | Commonly every 3 months; interpret with caution | KDIGO 2022 diabetes |
| Lipid profile | At baseline; routine follow-up not required for most patients | KDIGO 2013 lipids |
| Aluminum | When clinically indicated | MAT and KDIGO 2017 |
Surveyors do not cite a facility because one patient's value is out of range. They cite it when the IDT fails to recognize and act on out-of-range outcomes (MAT, plan-of-care section).
Targets and where they come from
| Parameter | Target or threshold | Source and notes |
|---|---|---|
| Pre-dialysis potassium | Keep in the normal range; many units use 3.5–5.5 mEq/L | KDOQI 2020 6.4.1 (OPINION) |
| Phosphorus (dialysis) | 3.5–5.5 mg/dL (survey tool); lower elevated values toward normal | MAT; KDIGO 2017; KDOQI 2020 6.3.1 (normal range, 1B) |
| Phosphorus (non-dialysis CKD) | Normal lab range (about 2.5–4.5 mg/dL) | KDOQI 2020; KDIGO 2017 |
| Calcium | Avoid hypercalcemia; survey tool: uncorrected calcium in the lab's normal range or below 10.2 mg/dL (3-month rolling average) | KDIGO 2017; MAT |
| Intact PTH (G5D) | About 2–9 times the assay upper limit; act on trends | KDIGO 2017 |
| Bicarbonate | KDOQI: 24–26 mmol/L (OPINION); KDIGO 2024: consider treatment below about 18 mmol/L, not above normal | Sources differ |
| Albumin | Survey tool: at least 4.0 g/dL by BCG, or lab normal by BCP; ISRNM PEW criterion below 3.8 g/dL by BCG | MAT; ISRNM 2008 |
| Hemoglobin on ESA | Keep below 11.5 g/dL during maintenance; consider starting an ESA at 9.0–10.0 g/dL or lower in dialysis | KDIGO 2026; FDA labeling warns against targeting above 11 g/dL |
| Ferritin and TSAT (HD) | Start iron when ferritin is 500 ng/mL or less and TSAT 30% or less; hold routine iron when ferritin is above 700 ng/mL or TSAT 40% or higher | KDIGO 2026 |
| HbA1c (diabetes) | Individualized, from below 6.5% to below 8.0%; unreliable in advanced CKD and dialysis | KDIGO 2022 |
Correcting calcium for albumin
About 40–45% of serum calcium is bound to albumin, so low albumin makes measured total calcium look low. The Payne formula estimates corrected calcium:
Correction formulas often misclassify calcium status in dialysis patients. Measure ionized calcium when the answer matters, for example with severe hypoalbuminemia, acid–base disturbance, or symptoms. The ESRD QIP and the survey tool use uncorrected total calcium to avoid formula differences.
Why the calcium × phosphorus product was dropped
The KDOQI 2003 bone guideline recommended keeping the calcium × phosphorus product below 55 mg²/dL². KDIGO (2009, and again in 2017) stopped recommending it, because the product adds little beyond the separate calcium and phosphorus values and can hide which one is abnormal. Current practice treats phosphorus toward normal and avoids hypercalcemia as separate goals. You may still see the product on older materials and questions, so know the number, but reason with the components.
Reading PTH
Intact PTH assays differ, so KDIGO expresses the dialysis target as a multiple of the upper limit of normal (about 2–9 times). Rising trends toward the upper end call for attention to phosphorus, 25(OH)D, calcium and PTH-lowering drugs. Values persistently below about 2 times the upper limit, especially with low alkaline phosphatase, suggest adynamic bone disease from over-suppression by calcium loading, active vitamin D or calcimimetics.
Albumin: the assay matters
Bromocresol green (BCG) also binds some globulins and reads higher than bromocresol purple (BCP), which is more specific. The difference is often several tenths of a g/dL in dialysis patients. Interpret albumin against the method your lab uses. The ISRNM PEW criterion (below 3.8 g/dL) and the survey tool's 4.0 g/dL value refer to BCG. KDOQI 2020 recognizes albumin as a strong predictor of hospitalization and death in maintenance HD (statement 1.2.2, grade 1A), but it cautions that albumin, prealbumin and nPCR are influenced by non-nutritional factors such as inflammation and should not be read in isolation (1.2.1).
Trends versus isolated values
| Pattern | Likely explanation | Nutrition action |
|---|---|---|
| Sudden potassium spike (e.g., 4.6 to 6.3 mEq/L) | Dietary excess, a new drug, GI bleeding, acidosis, constipation, a missed treatment, or a hemolyzed sample | Repeat if hemolysis is suspected; review 72-hour intake, drugs, bowel habits and the dialysate bath |
| Gradual potassium rise over months | Loss of residual function, new RAAS blockade, chronic constipation | Adjust the diet plan; discuss a binder or bath change with the team |
| Sudden albumin drop (e.g., 4.1 to 3.1 g/dL) | Inflammation or infection, such as an access infection or pneumonia | Look for infection first; do not simply add protein |
| Slow albumin decline over 6 months | Progressive PEW, poor intake or inadequate dialysis | Full reassessment: NFPE, intake, nPCR; supplements |
| High phosphorus with low nPCR | Additive-rich processed foods | Additive education; protect protein intake |
| Low phosphorus with low nPCR | Starvation or binder overdose | Reduce binders; nutrition support |
Draw timing and rebound
- Draw monthly panels before dialysis, before heparin or saline.
- Post-dialysis samples are hemoconcentrated for large molecules (albumin, hemoglobin) and reflect urea removal.
- Post-dialysis urea rebound (BUN rising as urea moves out of cells and poorly perfused tissues) is largely complete within 30–60 minutes. Adequacy sampling uses standardized slow-flow or stop-dialysate-flow techniques (section 13.1).
Putting it together
For each monthly review, the dietitian should: (1) compare values with the right target and its source; (2) look at the trend across at least three months; (3) consider non-diet causes (drugs, dialysis dose, inflammation, sampling); (4) choose one or two priority problems for the PES statements; and (5) record the plan and the recheck date in the plan of care.
A hemodialysis patient's monthly labs show measured total calcium 8.0 mg/dL, albumin 2.5 g/dL, phosphorus 6.4 mg/dL and potassium 4.8 mEq/L. What is the corrected calcium, and what is the best interpretation?
Corrected calcium is 8.0 mg/dL; no correction is needed and the mineral profile is on target.
Corrected calcium is 6.8 mg/dL; the patient needs intravenous calcium during dialysis.
Corrected calcium is 9.6 mg/dL; the values prove adynamic bone disease, so all binders should stop.
Corrected calcium is 9.2 mg/dL; the calcium × phosphorus product (about 59) exceeds the old KDOQI 2003 ceiling of 55, but the actionable problem is the high phosphorus, which current guidance says to lower toward normal.
A 55-year-old male with ESRD on peritoneal dialysis has quarterly laboratory surveillance completed. Over the past 9 months, his intact parathyroid hormone (iPTH) has progressively drifted from 320 pg/mL down to 68 pg/mL, while his total alkaline phosphatase dropped from 85 U/L to 38 U/L. His corrected serum calcium is 10.1 mg/dL and phosphorus is 4.4 mg/dL. He is currently prescribed calcium carbonate 1,000 mg three times daily with meals and oral calcitriol 0.5 mcg daily. How should the interdisciplinary nephrology team interpret these trends, and what intervention is indicated?
The patient is developing high-turnover osteitis fibrosa cystica due to insufficient calcitriol dosing; calcitriol should be escalated to 1.0 mcg daily to suppress alkaline phosphatase further.
The patient has developed low-turnover adynamic bone disease secondary to iatrogenic oversuppression of the parathyroid glands; calcitriol should be discontinued or tapered and calcium carbonate transitioned to a non-calcium phosphate binder.
The biochemical findings indicate ideal mineral homeostasis because lower iPTH levels (<100 pg/mL) completely eliminate the risk of skeletal fractures and vascular calcification; no changes should be made.
The patient has severe osteomalacia resulting from aluminum intoxication; deferoxamine therapy should be initiated immediately and dietary phosphorus increased.
A 49-year-old female on maintenance hemodialysis undergoes quarterly anemia and iron surveillance. Her laboratory results show: hemoglobin 9.4 g/dL, serum ferritin 920 ng/mL, transferrin saturation (TSAT) 16%, and high-sensitivity C-reactive protein (hs-CRP) 28 mg/L (normal <3.0 mg/L). Her dialysis access is a mature left forearm arteriovenous fistula with no outward erythema or warmth. The clinical team evaluates whether to administer intravenous iron sucrose. What is the most accurate clinical interpretation and management plan?
The low TSAT of 16% confirms severe absolute iron deficiency; high-dose IV iron (1,000 mg load) should be administered immediately because ferritin values are negligible in hemodialysis.
The patient has hemochromatosis caused by chronic iron overload; therapeutic phlebotomy should be initiated and all erythropoiesis-stimulating agents immediately discontinued.
The patient has functional iron deficiency (reticuloendothelial iron blockade) driven by inflammation; routine IV iron should be held because ferritin is above the 700 ng/mL level at which KDIGO 2026 advises withholding it, and the inflammatory source should be sought.
Oral ferrous sulfate 325 mg three times daily should be prescribed with meals because oral iron bypasses hepatic hepcidin regulation and avoids inflammatory sequestration.
Sections you finish are checked off in the contents.